Gel Column Agglutination Test System Market By Product Type (Reagents & Gel Cards, Instruments & Analyzers, Software & Accessories, Consumables & Controls); By Test Type (Antibody Screening, Blood Grouping, Crossmatching, Antibody Identification, Direct Antiglobulin Test); By Application (Blood Typing & Cross-Matching, Compatibility Testing, Antibody Screening, Other Immunohematology Tests); By End User (Hospitals & Blood Banks, Diagnostic Laboratories, Academic Medical Centers, Research Institutions, Pharmaceutical Companies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Gel Column Agglutination Systems Move From Manual Serology to Connected Transfusion Workflows – (Updated On: 16-Sep-2026)

The Global Gel Column Agglutination Test System Market was valued at USD 1.40 billion in 2025 and is projected to reach USD 2.15 billion by 2032, expanding at a CAGR of 6.35% during 2026–2032, according to Strategic Market Research.

 

Gel column agglutination (GCA) systems are advanced immunohematology platforms used by blood banks and transfusion laboratories to ensure safe and compatible blood transfusions. The technology detects red blood cell reactions by separating agglutinated and non-agglutinated cells within gel-filled microcolumns during centrifugation. This enables standardized interpretation of results for critical testing procedures, including ABO/Rh blood grouping, antibody screening, crossmatching, antibody identification, and direct antiglobulin testing (DAT).

 

Compared with conventional tube-based testing, gel technology improves laboratory performance through higher reproducibility, standardized reaction grading, permanent result storage, reduced operator variability, and integration with automated analyzers and laboratory information systems (LIS). These advantages have accelerated adoption among hospital blood banks, reference laboratories, and centralized transfusion centers seeking improved efficiency, quality control, and regulatory compliance.

 

The product landscape includes manual gel cards, centrifuges, incubators, digital readers, middleware solutions, and fully automated immunohematology analyzers. Leading platforms include Bio-Rad IH-500 and IH-1000, Grifols Erytra and Erytra Eflexis, and QuidelOrtho ORTHO VISION systems. These systems compete on testing throughput, automation level, workflow integration, result traceability, and recurring consumable requirements. Analyzer installations also create ongoing revenue opportunities through gel cards, reagent red cells, antisera, controls, software support, maintenance contracts, and laboratory services.

 

The market is supported by the growing global demand for transfusion services. According to the World Health Organization (WHO), approximately 120.4 million blood donations are collected worldwide each year, creating a large and recurring need for donor testing, blood typing, antibody detection, and compatibility assessment. High-income countries account for approximately 36% of global blood donations despite representing only 15% of the world population, reflecting greater adoption of automated blood-processing and immunohematology technologies. In these markets, nearly 98% of collected blood is processed into components, increasing the complexity and volume of laboratory testing requirements.

 

The United States represents one of the largest commercial markets due to its advanced transfusion infrastructure and high testing demand. The 2023 National Blood Collection and Utilization Survey (NBCUS) reported approximately 11.58 million red blood cell units collected and 10.32 million units transfused in the U.S. Each transfusion pathway requires multiple compatibility assessments, including blood grouping, antibody screening, and crossmatching, supporting continuous demand for immunohematology reagents and automation platforms.

 

Overall, the Gel Column Agglutination Test System Market is evolving from a laboratory testing technology into a broader transfusion-management ecosystem. Future growth will be driven by increasing transfusion activity, automation of blood banks, expansion of centralized testing networks, and the global shift toward safer, faster, and more standardized compatibility testing solutions.

 

Complete Segment Snapshot Across Products, Tests, Applications, End Users, and Regions in the Gel Column Agglutination Test System Market

Product Type:

• Reagents & Gel Cards: The leading product segment held 55% of the market and USD 770 million in 2025, supported by recurring card, reagent-cell, and antisera consumption.

• Instruments & Analyzers: The segment accounted for 28% and USD 390 million, with laboratories investing in automated processing, digital interpretation, and replacement systems.

• Software & Accessories: This category represented 10% and USD 140 million as blood banks added middleware, barcode tracking, data archiving, and laboratory system connectivity.

• Consumables & Controls: The segment held 7% and USD 100 million, supported by daily quality control, verification, cleaning, and routine operating requirements.

 

Test Type:

• Antibody Screening: The leading test category captured 32% and USD 450 million due to its routine position in detecting unexpected antibodies before transfusion.

• Blood Grouping: The segment held 26% and USD 365 million, anchored by continuous ABO and Rh typing across donor and patient workflows.

• Crossmatching: This category represented 20% and USD 280 million because donor–recipient compatibility confirmation remains central to blood release.

• Antibody Identification: The segment accounted for 15% and USD 210 million, with complex cases generating use of identification panels and specialized reagents.

• Direct Antiglobulin Test: DAT held 7% and USD 95 million through its use in transfusion-reaction investigations and immune-mediated red-cell destruction.

 

Application:

• Blood Typing & Cross-Matching: The dominant application accounted for 38% and USD 530 million because it forms the operational core of pretransfusion testing.

• Compatibility Testing: This application held 27% and USD 380 million, supported by surgery, oncology, transplant, trauma, and chronic transfusion care.

• Antibody Screening: The segment represented 25% and USD 350 million across recipient testing, prenatal assessment, donor screening, and transfusion-safety programs.

• Other Immunohematology Tests: The category held 10% and USD 140 million, covering phenotyping, antibody titration, rare-antigen work, neonatal testing, and research applications.

 

End User:

• Hospitals & Blood Banks: The leading end-user category held 60% and USD 840 million due to its central role in routine, emergency, and complex transfusion support.

• Diagnostic Laboratories: The segment accounted for 22% and USD 310 million as health systems centralized specialized immunohematology testing.

• Academic Medical Centers: These centers represented 8% and USD 110 million through advanced transfusion care, training, and complex antibody investigations.

• Research Institutions: The category held 6% and USD 85 million, supported by blood-group research, method comparison, and reagent development.

• Pharmaceutical Companies: The segment accounted for 4% and USD 55 million through specialized clinical research and transfusion-related laboratory work.

 

Geography:

• North America: The leading regional market held 38% and USD 530 million, supported by mature blood-bank automation and established laboratory networks.

• Europe: The region represented 30% and USD 420 million, with national blood services and centralized laboratories sustaining gel-card consumption.

• Asia Pacific: The fastest-growing region held 22% and USD 310 million as hospitals and blood centers replaced manual workflows with automated platforms.

• Latin America: The region accounted for 6% and USD 85 million through laboratory modernization in major public and private healthcare centers.

• Middle East & Africa: The region held 4% and USD 55 million, with adoption concentrated in national blood services and tertiary hospitals

 

Recurring Gel-Card Revenue and Digital Integration Define Segment Leadership

Product Type

Reagents & Gel Cards are the leading product segment, accounting for 55% of the market and USD 770 million in 2025. Their leadership comes from repeat consumption: every blood grouping, antibody screening, crossmatching, phenotyping, or antiglobulin procedure requires compatible cards and reagents. An analyzer may remain operational for several years, but gel cards, reagent red cells, antisera, and diluents are purchased continuously. Suppliers such as Bio-Rad and Grifols benefit from this model because placements of their IH and Erytra systems create recurring use of ID-Cards and DG Gel cards. Reagent standardization and validated instrument–card combinations also make switching suppliers operationally difficult, protecting long-term account value.

Software & Accessories are the fastest-growing product segment, projected to expand at an estimated CAGR of 6.9% during 2026–2032. Blood banks are adding digital readers, middleware, barcode modules, electronic audit trails, reaction-image storage, and bidirectional laboratory information system connectivity. These technologies reduce manual transcription, strengthen sample traceability, and allow several analyzers or satellite laboratories to be managed through a centralized interface. Bio-Rad’s IH-Com and Werfen’s ImmuLINK illustrate how data-management tools are becoming part of the overall transfusion-testing contract rather than optional accessories. Software growth also benefits from upgrades within the existing analyzer base, avoiding dependence solely on new instrument placements.

 

Test Type

Antibody Screening is the leading test type, holding 32% of the market and USD 450 million in 2025. Screening is routinely performed before transfusion to identify unexpected antibodies that may react with donor red cells. A positive result often initiates additional antibody identification, phenotyping, crossmatching, and antigen-negative unit selection, increasing the number and value of tests generated from one patient sample. Screening is also relevant to prenatal testing and chronically transfused patients, including those receiving care for sickle cell disease, thalassemia, hematologic cancers, or transplant-related conditions. Bio-Rad, Grifols, and QuidelOrtho support this workflow through screening cells, antiglobulin cards, automated analyzers, and digital reaction interpretation.

Antibody Identification is the fastest-growing test type, projected to expand at an estimated CAGR of 7.1% during 2026–2032. Its growth is linked to complex transfusion populations, repeated transfusions, and greater use of extended antigen matching. Once an antibody screen becomes reactive, laboratories may require characterized red-cell panels, selected cells, enzyme-treated cells, neutral cards, rare antisera, and specialist interpretation to determine antibody specificity. These cases produce higher reagent use and greater laboratory value than routine negative screens. Software-assisted interpretation, broader identification panels, and integration with red-cell genotyping are also improving the ability of reference laboratories and academic medical centers to manage complex antibody profiles.

 

Application

Blood Typing & Cross-Matching is the leading application, accounting for 38% of the market and USD 530 million in 2025. These procedures form the operational foundation of pretransfusion testing because laboratories must establish the recipient’s blood group and verify compatibility before issuing red-cell units. Test volumes are linked to surgical care, trauma, oncology, transplantation, obstetrics, emergency medicine, and chronic transfusion programs. Automated systems from Bio-Rad, Grifols, and QuidelOrtho combine sample identification, card processing, reaction grading, result storage, and laboratory information system transfer, helping laboratories manage routine and urgent samples within the same workflow.

Other Immunohematology Tests form the fastest-growing application segment, with an estimated CAGR of 7.1% during 2026–2032. The category includes extended red-cell phenotyping, antibody titration, rare-antigen investigations, neonatal testing, and selected veterinary procedures. Extended phenotyping is becoming commercially relevant for multiply transfused or alloimmunized patients who may require antigen-negative blood beyond routine ABO and Rh matching. Gel-based antibody titration also offers more standardized dilution and reaction-reading workflows for selected maternal-fetal investigations. Bio-Rad’s IH-500 NEXT, for example, includes automated titration capabilities designed for gel cards, reducing manual dilution steps and strengthening result traceability.

 

End User

Hospitals & Blood Banks are the leading end-user segment, representing 60% of the market and USD 840 million in 2025. These facilities perform the largest recurring volumes of blood grouping, antibody screening, crossmatching, and transfusion-reaction investigations. Large blood centers require high-throughput systems with continuous loading and broad reagent capacity, while community hospitals often use compact analyzers or semi-automated platforms. Their market leadership also reflects the combined revenue generated by instruments, proprietary cards, reagent cells, controls, software, maintenance, training, and technical support. Reagent-rental contracts further strengthen this position by linking analyzer placement to multi-year consumable purchases.

Research Institutions are the fastest-growing end-user segment, projected to expand at an estimated CAGR of 7.0% during 2026–2032, although their absolute market share remains limited at 6% and USD 85 million in 2025. Growth comes from rare blood-group research, antibody characterization, evaluation of new antisera, comparison of serologic methods, and development of specialized testing protocols. Research laboratories also contribute to the integration of gel-column testing with molecular blood-group genotyping. Their purchasing profile differs from routine blood banks because volumes are lower, but spending is more concentrated in specialized cards, characterized red-cell panels, rare reagents, and customized workflows.

 

Geography

North America is the leading regional market, accounting for 38% of global revenue and USD 530 million in 2025. Its position is supported by established transfusion services, extensive blood-bank automation, consolidated hospital networks, laboratory accreditation requirements, and a large installed analyzer base. Regional spending increasingly comes from analyzer replacement, middleware upgrades, cybersecurity, remote support, preventive maintenance, and recurring reagent contracts. Bio-Rad, Grifols, QuidelOrtho, and Werfen–Immucor compete across different testing technologies for the same blood-bank capital and consumable budgets.

Asia Pacific is the fastest-growing region, projected to expand at an estimated CAGR of 8.1% during 2026–2032. The region accounted for 22% of the market and USD 310 million in 2025. Hospital expansion, modernization of blood centers, growth of private diagnostic networks, and gradual replacement of manual tube testing are creating new installation opportunities. Japan, Australia, South Korea, Singapore, and major Chinese cities have relatively mature automation environments, while India and Southeast Asia offer broader opportunities for compact and semi-automated systems. Suppliers that combine scalable analyzers with affordable gel-card menus, distributor training, local maintenance, and reliable reagent availability are positioned to capture this transition.

 

Integrated Analyzer-Reagent Ecosystems Establish Bio-Rad’s Market Lead

Bio-Rad Laboratories — Leading Company

Bio-Rad Laboratories holds the strongest topic-specific position in the Gel Column Agglutination Test System Market because it combines a broad gel-card testing menu with automated analyzers, reagent red cells, antisera, controls, interpretation software, and laboratory connectivity. Its portfolio supports blood grouping, antibody screening, crossmatching, antibody identification, antigen phenotyping, direct antiglobulin testing, and antibody titration across laboratories with different testing volumes.

The company’s automated portfolio includes the IH-1000 for high-throughput blood banks and the IH-500 NEXT for medium-throughput laboratories. The IH-1000 provides continuous sample and reagent loading for laboratories requiring high-capacity operation, while the compact IH-500 NEXT reduces manual processing and supports automated titration using gel cards.

Bio-Rad’s competitive strength extends beyond analyzer placement. Each installed system supports recurring purchases of proprietary ID-Cards, screening cells, identification panels, antisera, controls, and cleaning materials. IH-Com connectivity adds workflow management, electronic result transfer, and centralized data handling. This analyzer–reagent–software structure gives Bio-Rad a durable commercial position because changing platforms may require laboratories to repeat validation, retrain staff, replace inventory, and reconfigure information-system connections.

Other Companies Positioned in the Gel Column Agglutination Test System Market

• Grifols: A major direct competitor with DG Gel cards, Erytra, and Erytra Eflexis, but positioned behind Bio-Rad in this assessment because its topic-specific portfolio is comparatively more concentrated around the DG Gel ecosystem.

• QuidelOrtho: A strong column-agglutination competitor through ORTHO BioVue, ORTHO VISION, ORTHO Workstation, and ORTHO OPTIX, but not identified as the top company because its platform breadth within gel-column testing is narrower than Bio-Rad’s integrated portfolio.

• Werfen–Immucor: An important automated immunohematology competitor through NEO Iris, Echo Lumena, Capture-R, and ImmuLINK, but not a direct gel-column leader because its principal automated platforms use solid-phase red-cell adherence technology.

 

Connected Immunohematology Ecosystems Define the Next Commercial Phase

The future growth of the Gel Column Agglutination Test System Market will move beyond simply replacing manual testing methods and toward building integrated transfusion management platforms. While analyzers and gel cards will remain the primary sources of revenue, additional growth opportunities will come from digital connectivity, automated result interpretation, laboratory data management, and remote monitoring solutions. Companies that combine instruments, consumables, software, and service support into a complete workflow solution will be better positioned to create long-term value for blood banks and hospitals.

A major opportunity exists in emerging healthcare markets, where many laboratories still rely on manual or semi-automated immunohematology testing. As these regions expand surgical care, trauma services, cancer treatment, and transplant programs, demand for reliable blood compatibility testing will increase. Manufacturers offering affordable automated systems, compact analyzers, local technical support, and flexible reagent supply models can accelerate adoption across Asia Pacific, Latin America, and Middle East & Africa.

Another growth area is the increasing complexity of modern transfusion medicine. The rising number of patients requiring repeated transfusions, advanced blood matching, rare antibody identification, and personalized antigen testing is creating demand for more sophisticated solutions. Future platforms that combine gel testing with digital patient records, antibody history tracking, and advanced interpretation tools can help laboratories improve accuracy and manage complex transfusion cases more efficiently.

The installed base of analyzers will also create ongoing commercial opportunities. As laboratories expand and modernize, demand will continue for instrument upgrades, software improvements, maintenance services, and replacement consumables. This recurring revenue model makes the market attractive beyond initial equipment sales and supports long-term supplier relationships with healthcare institutions.

Future competition will increasingly focus on complete laboratory ecosystems rather than individual analyzers. Companies that improve automation, traceability, workflow efficiency, and integration with hospital information systems will have stronger opportunities to differentiate their products.

Overall, the Gel Column Agglutination Test System Market is evolving toward a connected, automated, and data-driven transfusion care model. Growth will be driven by increasing blood transfusion needs, laboratory modernization, expanding healthcare access, and the global demand for safer and more standardized compatibility testing.

 

Gel Column Agglutination Test System Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.40 Billion
Revenue Forecast in 2032	USD 2.15 Billion
Overall Growth Rate	CAGR of 6.35% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Product Type, By Test Type, By Application, By End User, By Geography
By Product Type	Reagents & Gel Cards, Instruments & Analyzers, Software & Accessories, Consumables & Controls
By Test Type	Antibody Screening, Blood Grouping, Crossmatching, Antibody Identification, Direct Antiglobulin Test
By Application	Blood Typing & Cross-Matching, Compatibility Testing, Antibody Screening, Other Immunohematology Tests
By End User	Hospitals & Blood Banks, Diagnostic Laboratories, Academic Medical Centers, Research Institutions, Pharmaceutical Companies
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Japan, China, South Korea, India, Australia, Singapore, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing transfusion activity, recurring gel-card and reagent consumption, blood-bank automation, expansion of centralized testing networks, increasing complexity of compatibility testing, and adoption of connected laboratory information systems
Customization Option	Available upon request